EP2575758A1 - Formulation pour l'ostéoporose - Google Patents

Formulation pour l'ostéoporose

Info

Publication number
EP2575758A1
EP2575758A1 EP11764885.7A EP11764885A EP2575758A1 EP 2575758 A1 EP2575758 A1 EP 2575758A1 EP 11764885 A EP11764885 A EP 11764885A EP 2575758 A1 EP2575758 A1 EP 2575758A1
Authority
EP
European Patent Office
Prior art keywords
effervescent
formulation according
formulation
calcium
formulation comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11764885.7A
Other languages
German (de)
English (en)
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2575758A1 publication Critical patent/EP2575758A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the present invention relates to pharmaceutical formulations with high bioavailability comprising calcium, genistein and vitamin D in order to be used in prophylaxis and treatment of osteoporosis and related diseases.
  • Bone loss, or in other terms "osteoporosis” is defined as a disease characterized by liability to bone fracture and increased risk of bone fracture as a consequence of low bone mass and deterioration of bone micro architecture. The disease does not generally result in death; however, it is a major health problem affecting life quality.
  • osteoporosis is mostly seen in spine, hip and wrist; all the bones in the body are affected by the disease. 80% of the patients are female though the disease is encountered in both genders. Postmenopausal women lose 0,7-2% of total bone mass annually while this ratio is 0,5-0,7% for men. In parallel with this, total bone mass loss in men and women between 45-70 years of age is 15-30%. Some studies conducted nowadays indicate that insufficient calcium intake in childhood may increase the risk of osteoporosis later in life. It is known that calcium taken by diet plays a significant role in prophylaxis of osteoporosis. However, calcium absorption is reduced in postmenopausal term due to physical features of calcium and other factors.
  • Calcium salts in all calcium sources do not dissolve at an equal rate or present desired bioavailability.
  • Calcium salts have low water solubility. They are dissolved relatively better in gastric acid; however, carbon dioxide produced causes gas and pain in the stomach. Furthermore, gastric acid is reduced due to gastric acid inhibitors used in later ages and therefore calcium leaves the stomach without being dissolved.
  • Vitamin D deficiency Another factor for reduced calcium absorption in postmenopausal women is vitamin D deficiency.
  • Vitamin D is a fat-soluble hormone precursor and the studies conducted have indicated that efficient amounts of vitamin D increases calcium absorption. Vitamin D deficiency is also seen in individuals who do not receive sufficient sunlight.
  • calcitonin which is a calcium regulating hormone
  • osteoporosis treatment particularly in postmenopausal osteoporosis treatment in the cases where oestrogen treatment is not suitable.
  • use of this treatment method has remained limited as the patients started to resist this treatment and it is high cost.
  • various hormones contribute to calcium intake.
  • calcium and hormone combination has not been preferred due to the reasons such as side effects, resistance and cost.
  • genistein that is a phytoestrogen instead of oestrogen in recent years, bone mass could be increased without occurrence of the side effects observed in other hormone therapies.
  • genistein alleviates the symptoms observed in postmenopausal term such as hot flash and night sweat.
  • Tablet formulation comprising calcium, vitamin D and genistein that exists on the market now has been developed and put on the market in line with this purpose.
  • the individuals Due to the problems appearing particularly in pharyngeal and esophageal movements, the individuals may have a feel of obstruction or asphyxiation, and as a result, intake of the medicament may turn disgustful and painful for the patient.
  • Another disadvantage of tablet formulations comprising calcium is gas and pain in the stomach resulting from carbon dioxide produced while calcium is being dissolved in gastric acid.
  • effervescent formulations comprising calcium, vitamin D and genistein are more user-friendly, have fewer side effects and present higher bioavailability compared with tablet formulations; therefore, they display higher efficacy in the prophylaxis and treatment of osteoporosis and related diseases in comparison with existing formulations.
  • the present invention relates to effervescent formulations comprising calcium, vitamin D and genistein.
  • Effervescent formulation of the present invention can be in powder, granule, pellet, micro tablet or tablet form though it is preferably in tablet form.
  • Calcium used in the formulation of the present invention is preferably in salt form.
  • Calcium used in the formulation of the present invention can be selected fromcalcium, carbonate, chloride, phosphate, citrate, lactate, glubionate, gluceptate, gluconate salts though it is preferably carbonate salt.
  • Formulation of the present invention comprises 5-60% calcium or calcium salt by weight.
  • Formulation of the present invention comprises 200-2000 mg calcium or calcium salt in an equal amount to this.
  • the inventors Considering that calcium salts have low water solubility in general, the inventors have encountered solubility problems in development of effervescent dosage forms comprising calcium or calcium salt. The inventors could attain to efficient solubility when they used calcium or calcium salt with a particle size smaller than 100 ⁇ , preferably smaller than 60 ⁇ .
  • the present invention relates to effervescent formulations comprising calcium or calcium salt with a particle size smaller than 100 ⁇ , preferably smaller than 60 ⁇ , vitamin D and genistein.
  • Vitamin D comprised in the formulation of the present invention can be vitamin D 2 (ergocalciferol) or vitamin D 3 (cholecalciferol) though it is preferably vitamin D 3 (cholecalciferol).
  • Formulation of the present invention comprises 0,01-15% vitamin D by weight.
  • Formulation of the present invention comprises 200-1000 IU vitamin D.
  • Formulation of the present invention comprises 0,1-25% genistein by weight.
  • Formulation of the present invention comprises 10-70 mg, preferably 20-55 mg genistein.
  • the formulation of the present invention can comprise an effervescent couple to provide water solubility characteristic.
  • effervescent couple refers to use of an acidic agent and a basic agent together.
  • the pharmaceutically acceptable acidic agent of the present invention can be selected from a group comprising acetic acid, citric acid, lactic acid, malic acid, phosphoric acid, propionic acid, tartaric acid or combinations thereof.
  • the pharmaceutically acceptable acidic agent used in the formulation of the present invention is preferably citric acid, malic acid or a combination thereof.
  • the pharmaceutically acceptable basic agent of the present invention can be selected from a group comprising potassium carbonate, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate, sodium hydrogen citrate or combinations thereof.
  • the pharmaceutically acceptable basic agent used in the formulation of the present invention is preferably sodium carbonate, sodium hydrogen carbonate or a combination thereof.
  • the effervescent formulation of the present invention can optionally comprise one or more of the excipients including diluent, binder, glidant, lubricant, disintegrant, flavoring agent, sweetener, coloring agent, surfactant, anti-foam agent, stabilizing agents.
  • excipients including diluent, binder, glidant, lubricant, disintegrant, flavoring agent, sweetener, coloring agent, surfactant, anti-foam agent, stabilizing agents.
  • the said diluents can be selected from a group comprising lactose, maltose, dextrin, maltodextrin, mannitol, sorbitol, starch or a combination thereof.
  • solubility rate is increased when they use less than 15% diluent by weight in the formulation.
  • the said binder can be selected from a group comprising starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums; gelatin; cellulose derivatives such as microcrystalline cellulose, HPC, HEC, HPMC, carboxymethyl cellulose, methyl cellulose, ethyl cellulose; polyvinylpyrrolidone (povidone), polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols such as sorbitol, xylitol, mannitol, and water or a combination thereof though it is preferably lactose, povidone, polyethylene glycol or a combination thereof.
  • starches such as potato starch, corn starch, wheat starch
  • sugars such as sucrose, glucose, dextrose, lactose, maltodextrin
  • natural and synthetic gums gelatin
  • cellulose derivatives such as
  • the said glidant can be selected from a group comprising sodium lauryl sulfate, sodium benzoate, sodium chloride, sodium acetate, sodium fumarate, carbowax 4000, L-leucine(17), PEG or a combination thereof.
  • the said lubricant can be selected from a group comprising talc, magnesium stearate, stearic acid, sodium stearil fumarate, polyoxyethylene glycol, leucine, alanine, glycine, sodium benzoate, sodium acetate, fumaric acid or a combination thereof.
  • the said disintegrant can be selected from a group comprising starches such as potato starch, corn starch, wheat starch, pregelatinized starch, sodium starch glycolate; cellulose derivatives such as croscarmellose sodium or microcrystalline cellulose; polyvinylpyrrolidone; crospovidone; alginic acid and its salts; clays such as xanthan gum or Veegum; ion exchange resins or a combination thereof.
  • the said flavoring agent can be selected from a group comprising natural aroma oils (peppermint oil, wintergreen oil, clove bud oil, parsley oil, eucalyptus oil, lemon oil, orange oil), menthol, menthane, anethole, methyl salicylate, eucalyptol, cinnamon, 1 -methyl acetate, sage, eugenol, oxanone, alpha irisone, marjoram, lemon, orange, blackberry, propenyl guaetol acetyl, cinnamon, vanilla, thymol, linalol, cinnamaldehyde glycerol acetal, N-substituted p- menthane-3-carboxamide, 3,1-methoxy propane 1,2-diol or a combination thereof though it is preferably lemon, orange, blackberry flavor or a combination thereof.
  • natural aroma oils peppermint oil, wintergreen oil, clove bud oil, parsley oil,
  • the said sweetener can be selected from a group comprising sucralose, sucrose, fructose, glucose, galactose, xylose, dextrose, laevulose, lactose, maltose, maltodextrin, mannitol, maltitol, maltol, sorbitol, xylitol, erythritol, lactitol, isomalt, corn syrup, saccharine, saccharine salts, acesulfame potassium, aspartame, D-tryptophane, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, alitame, stevioside and cyclamates or a combination thereof though it is preferably sucralose, lactose, glucose, mannitol, sorbitol or a combination thereof.
  • the said surfactant can be selected from a group comprising sodium lauryl sulfate and magnesium lauryl sulfate or a combination thereof.
  • the said antifoam agent can be selected from a group comprising simethicone emulsion and dimethyl siloxane, silicon oil or a combination thereof.
  • the said stabilizing agent and/or agents can be selected from a group comprising antioxidants, chelating agents, alkalinizing agents and photoprotective agents.
  • the antioxidants can be selected from substances including butylated hydroxyanisole (BHA), sodium ascorbate, butylhydroxytoluene (BHT), sodium sulphite, gallates (such as propyl gallate), tocoferole, citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate or a combination thereof.
  • BHA butylated hydroxyanisole
  • BHT butylhydroxytoluene
  • gallates such as propyl gallate
  • tocoferole citric acid, malic acid, ascorbic acid, acetylcysteine, fumaric acid, lecithin, ascorbyl palmitate, ethylenediamine tetraacetate or a combination thereof.
  • the chelating agents can be selected from a group comprising disodium EDTA, edetic acid, citric acid, sodium citrate, potassium citrate or a combination thereof.
  • the alkalinizing agents can be selected from alkali metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophospate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; and primary, secondary and tertiary amines, cyclic amines; ⁇ , ⁇ '- dibenzyl ethylenediamine, dietanolamine, ethylenediamine, meglumine, monosodium glutamate, pola
  • the photoprotective agents can be selected from metal oxides such as titanium oxide, iron oxide and zinc oxide or a combination thereof.
  • the effervescent formulation of the invention comprises;
  • Effervescent couple in the range of 20-90% by weight
  • osteoporosis and related diseases comprises diseases such as osteoporosis; bone fracture including vertebral column and hip bones in postmenopausal women; bone fracture in men; idiopathic osteoporosis; osteoporosis resulting from various diseases; steroid and glucocorticoid-induced osteoporosis; osteopenia; osteomalacia; osteogenesis imperfecta; osteochondrodisplasia; sudeck atrophy; rheumatoid arthritis; Paget's disease; metastasis of malignant tumors to bones; hypercalcemia; or hyperthyroidism.
  • prophylaxis of the disease refers to prevention of abovementioned diseases by administering said formulations to healthy people. This term also comprises use of said formulation in people who are in the first stage of the disease.
  • treatment of the disease refers to use of the formulation of the present invention for treatment purposes in people diagnosed with osteoporosis or osteoporosis-related diseases.
  • the effervescent formulation of the present invention can be produced by direct compression, wet granulation and/or dry granulation methods applied conventionally.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiques avec une biodisponibilité élevée comprenant du calcium, de la génistéine et de la vitamine D destinées à être utilisées dans la prophylaxie et le traitement de l'ostéoporose et de maladies associées.
EP11764885.7A 2010-06-03 2011-06-02 Formulation pour l'ostéoporose Withdrawn EP2575758A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/04464A TR201004464A2 (tr) 2010-06-03 2010-06-03 Kemik erimesi için formülasyon.
PCT/TR2011/000150 WO2012002918A1 (fr) 2010-06-03 2011-06-02 Formulation pour l'ostéoporose

Publications (1)

Publication Number Publication Date
EP2575758A1 true EP2575758A1 (fr) 2013-04-10

Family

ID=44759752

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11764885.7A Withdrawn EP2575758A1 (fr) 2010-06-03 2011-06-02 Formulation pour l'ostéoporose

Country Status (3)

Country Link
EP (1) EP2575758A1 (fr)
TR (1) TR201004464A2 (fr)
WO (1) WO2012002918A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013043142A1 (fr) * 2011-08-08 2013-03-28 Mahmut Bilgic Procédé de production pour formulations pharmaceutiques comprenant une isoflavone
WO2013089654A1 (fr) * 2011-12-16 2013-06-20 Mahmut Bilgic Formulations effervescentes comprenant de la génistéine
AU2013346766B2 (en) * 2012-11-16 2018-05-24 Eusa Pharma (Uk) Ltd Effervescent tablet
CN105616441B (zh) * 2014-11-05 2018-08-14 澳美制药厂有限公司 碳酸钙维生素d3片及其制备方法
RU2582973C1 (ru) * 2015-03-10 2016-04-27 федеральное государственное бюджетное учреждение "Северо-Западный федеральный медицинский исследовательский центр" Министерства здравоохранения Российской Федерации (ФГБУ "СЗФМИЦ" Минздрава России) Антиостеопорозное средство
US10881634B2 (en) * 2017-12-07 2021-01-05 Hughes Biotechnology Co., Ltd Method for treatment or prevention of a disease associated with a decrease in bone mass and method of improving bone architecture and bio mechanical strength of bone
CN109172531A (zh) * 2018-09-04 2019-01-11 安士制药（中山）有限公司 一种复合碳酸钙/维生素d3片剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1852115A1 (fr) * 2001-03-15 2007-11-07 DSM IP Assets B.V. Composition pour la prévention de l'ostéoporose comprenant une combinaison d'isoflavones et d'acides gras polyinsaturés
ITFI20030194A1 (it) * 2003-07-17 2005-01-18 Menarini Int Operations Lu Sa Composizione farmaceutiche effervescenti contenenti
CN1589786A (zh) * 2003-09-01 2005-03-09 郑州博凯医药保健品有限公司 一种含大豆异黄酮的复合泡腾制剂
ES2390965T3 (es) * 2003-09-19 2012-11-20 Sunstar Inc. Procedimiento para inhibir la resorción ósea alveolar y la pérdida de membrana periodontal y composición para la utilización interna destinada a su utilización en el mismo
US20070207225A1 (en) * 2006-03-03 2007-09-06 Francesco Squadrito Genistein modulated reduction of cardiovascular risk factors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012002918A1 *

Also Published As

Publication number Publication date
TR201004464A2 (tr) 2012-11-21
WO2012002918A1 (fr) 2012-01-05

Similar Documents

Publication Publication Date Title
EP2575796A1 (fr) Formulations comprenant du calcium, de la vitamine d et de la vitamine k pour traiter l'ostéoporose
EP2575758A1 (fr) Formulation pour l'ostéoporose
EP1837019B1 (fr) Compositions pharmaceutiques orodispersibles
WO2010090614A1 (fr) Formulation pharmaceutique comprenant du risédronate, du carbonate de calcium et de la vitamine d3 combinés en une forme posologique unique
EP2496222B1 (fr) Compositions pharmaceutiques comprenant du calcium et de la vitamine d
WO2010101537A1 (fr) Composition pharmaceutique de principes actifs combinés en forme posologique unique
EP2393478B1 (fr) Compositions pharmaceutiques à l'odeur et au goût masqués hautement biodisponibles
EP2661252A1 (fr) Formes galéniques solubles dans l'eau
US20130164342A1 (en) Formulations for osteoporosis
ES2192136B1 (es) Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
EP2642980B1 (fr) Formulation pédiatrique
WO2010090612A1 (fr) Compositions pharmaceutiques stables, à goût et odeur masqués
EP2709596A1 (fr) Préparations effervescentes contenant du dexkétoprofène
EP2661270A1 (fr) Formes posologiques solubles dans l'eau comportant de l'ibandronate
EP2661262B1 (fr) Formulations améliorées de bisphosphonates
WO2012093971A2 (fr) Compositions effervescentes contenant de l'amlodipine
EP2661258B1 (fr) Formulation améliorée à base de risédronate
WO2010090613A1 (fr) Composition pharmaceutique combinée sous une forme posologique unique
WO2012026904A1 (fr) Forme galénique unidose réalisée à partir d'une combinaison comprenant du donépézil et de l'extrait de ginkgo biloba
EP2661257B1 (fr) Formulations effervescentes de bisphosphonate
WO2021061066A1 (fr) Formulations effervescentes de dichlorhydrate de saproptérine
WO2012026903A1 (fr) Compositions synergiques comprenant de la mémantine et de l'extrait de gingko biloba
TW201828936A (zh) 穩定且適口之維生素c及鋅組合物口含錠
JPH09157174A (ja) カルシウム製剤
WO2013055302A1 (fr) Composition effervescente comprenant de la n- acétylcystéine, de la doxophylline ou de la théophylline

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121231

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140828